Futura Medical Share Discussion Threads

[petroc] 17/12/2022 13:53

You still here, LiarBO?

[lbo] 17/12/2022 13:36

Long standing shareholders learned from Futura what clauses have been in previous deals that favour Futuras partners. Just to get the deals signed and announced. But allows the partners to never have to launch or if they do launch never have to pay any real royalties to Futura. There was zero value to shareholders in every so called distribution deal FUM have signed since 2003. And the signed deals even just allow partners to hand back the rights with no real penalties after sitting on the rights and running down any patents eg Reckitt and CSD500. Or what shareholders remember the deal with Kabey who was supposedly ‘ well established group’ and ‘exciting times’ were ahead! Yet Kabey itself no longer even exists?

And now we have companies like Eroxon limited being set up from a flat! LOL










a agreed percentage of the net sales value (after transport costs, sales tax, credit notes for returns and defective products and any settlement, retrospective, volume and promotional discounts) charged by LRC or any sub-licensee in relation to the Product.

The royalty and the royalty advance may be reduced by such amount (if any) as is agreed or determined by an expert to be fair and reasonable if: (i) any patent application does not proceed to grant or any patent rights are determined to be unenforceable or are revoked or lapse; or (ii) an event occurs which in LRC reasonable opinion adversely affects the commercial viability of the licence agreement or the margins on sales of the Product; or (iii) a competing product is offered

[petroc] 17/12/2022 12:58

Is there much point in stock bashing at the weekend, LiarBO?

[petroc] 17/12/2022 12:57

Tsk tsk LiarBO, you were 10 minutes late.

[lbo] 17/12/2022 11:39

Why has there been no update on any enforceable patent?



In Q2 2022 national applications will need to be made and the Company, in consultation with its commercial partners, will decide those countries in which to file applications and considered necessary to protect the commercial interests of MED3000. If national applications are successful



Most third party challenges to patentability occur in front of national or regional patent offices. WIPO recently released a summary of data regarding the extent to which third parties are challenging patentability at the international level. Any member of the public can file Third Party Observations against a PCT application during the international phase.


And how does a company expect to patent something that was clearly already described in research literature!? Whch they also admitted!



The Company has conducted initial literature and in vitro based research that has shown the cooling from the evaporation of these specific combinations of solvents



There is a risk that some claims will either be challenged in future (eg on the grounds of non-obviousness or existence of prior art) and/or that another technology may be employed to achieve a similar effect. The protracted development times mean the clock has been ticking on the original issued patents, reducing the protected commercial products




A smooth gel intended for alcohol soluble actives. Provides cooling effect upon application while leaving minimal residue




The cooling effect of a topically applied product can be evaluated using a validated handheld thermal imaging system. When the gel matrix is destroyed after application to the skin, the bound water and alcohol evaporates and a measurable cooling-effect results.


The brokers also admit they are assuming the original Med2002/2005 patents which expire in 2025 in EU and USA in 2028 will provide some protection to Med3000 until then. Thats a big assumption as the original patent was an umbrella patent covering Dermasys with GTN. Med3000 is just Dermasys on its own and now just a medical device delivering only a cooling sensation via ‘evaporative cooling’



intellectual property protection is limited to use patents for the individual products and umbrella patents for the technology. There is a risk that some claims will either be challenged in future (eg on the grounds of non-obviousness or existence of prior art) and/or that another technology may be employed to achieve a similar effect.
The protracted development times mean the clock has been ticking on the original issued patents, reducing the protected commercial product


So no enforceable additional patent has still been granted. Its even questionable if that application protects Med3000 as its all about ‘methods of measuring the cooling abaility of a topical composition’. Presumably because GSK used a handheld device thermal device to measure the cooling of their alcohol and water gel so Futura have to make their patent look different! LOL

And Dermasys on its own has no patent anymore as Dermasys itself dates back to 2002.

[petroc] 17/12/2022 11:24

How did the stock bashing go this week, LiarBO? Bwahahaha!

[petroc] 17/12/2022 11:23

Back to 5 minute response time again, LiarBO. Good boy!

[lbo] 17/12/2022 10:35

All Futura have done with MED3000 is open the door for Reckitt to sell similar lubricants/arousal gels as medical device placebo treatments for ED. And report Med3000 to the ASA, FTC etc for being misleading if it doesn’t inform consumers that MED3000 itself has no proven effect in ED beyond a placebo. As it has no proven efficacy in an adequate placebo controlled study or even against any standard cooling lubricant/arousal gels in an ED study.



‘You are the active ingredient’

Even the analysis on market forecasts knows Reckitt who is the market leader in lubricants will be only one to gain from marketing lubricants as placebo treatments for Erectile Dysfunction




Reckitt Benckiser was the defined leader and the ultimate four Personal lubricant vendors with leading brands such as Durex Play and K-Y Jelly.

KEY GROWTH FACTORS

Increasing prevalence of erectile dysfunction

9 Market Growth Enablers
9.1 Increasing Prevalence of Erectile Dysfunction

[petroc] 17/12/2022 10:29

Stop fantasising about your feminine arousal balm again, LiarBO!

[petroc] 17/12/2022 09:22

How did your imaginary short pan out, Truant?

[truant2tb1] 17/12/2022 00:16

Lol MED3000 - a placebo - is going to fly off the shelves for $5 an application when punters can get Sildenafil for 71p a pop (same med as Viagra which actually works!)…

ED sufferers will want something that actually works and is discreet… “oh hang on luv whilst I put my ED gel on”

This is comical. Only suckers and Lombard Odier fall for this nonsense